Status:
UNKNOWN
Evaluation of Omeprazole Effect on Glaucoma
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Collaborating Sponsors:
Ophthalmic Research Center
Conditions:
Glaucoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omepr...
Detailed Description
Omeprazole is a safe drug listed in OTC drug due to its safety. It acts by irreversible inhibition of K/H ATP ase pump and also Na/K ATP ase, Na/H ATP ase.Considering these actions the effect of omepr...
Eligibility Criteria
Inclusion
- patients with glaucoma
- 18 to 70 years
- POAG patients, Pseudoexfoliation
- no history of other systemic disease
- no history of intraocular intervention
- no history of H2 blocker or PPI consumption during the past month consuming 2 or less topical anti-glaucoma medication
- no present immune deficiency
- no addiction habit
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01000220
Last Update
May 4 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ophthalmic Research Center
Tehran, Tehran Province, Iran, 166666